tiprankstipranks
Trending News
More News >
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Hong Kong Market

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Financial Statements

Compare
0 Followers

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Financial Overview

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H's market cap is currently HK$8.25B. The company's EPS TTM is HK$-0.908; its P/E ratio is ―; ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H is scheduled to report earnings on ―, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue¥ 74.15M¥ 386.00K¥ 538.00K¥ 5.07M
Gross Profit¥ 74.15M¥ 424.65K¥ 538.00K¥ 5.07M
Operating Income¥ -308.04M¥ -364.67M¥ -402.11M¥ -734.38M
EBITDA¥ -295.63M¥ -355.35M¥ -384.49M¥ -718.88M
Net Income¥ -315.86M¥ -379.46M¥ -402.89M¥ -732.95M
Balance Sheet
Cash & Short-Term Investments¥ 752.12M¥ 608.56M¥ 635.21M¥ 668.33M
Total Assets¥ 922.00M¥ 874.59M¥ 839.98M¥ 892.84M
Total Debt¥ 136.36M¥ 74.77M¥ 14.62M¥ 18.54M
Net Debt¥ -341.24M¥ -232.21M¥ -620.59M¥ -649.79M
Total Liabilities¥ 243.69M¥ 126.30M¥ 60.76M¥ 2.49B
Stockholders' Equity¥ 678.90M¥ 748.29M¥ 779.22M¥ -1.60B
Cash Flow
Free Cash Flow¥ 0.00¥ -370.25M¥ -261.93M¥ -315.79M
Operating Cash Flow¥ 0.00¥ -367.55M¥ -238.71M¥ -190.54M
Investing Cash Flow¥ 0.00¥ -294.85M¥ 49.00K¥ -108.72M
Financing Cash Flow¥ 0.00¥ 331.04M¥ 179.38M¥ 793.03M
Currency in CNY

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Earnings and Revenue History

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Debt to Assets

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Cash Flow

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis